I also like these numbers, and the sentiment doesn't change, but fairly conservatively I'd be using US$420 net revenue per script (assuming a volume discount materialises over time), 25-35% NPAT margin, 2.2Bn shares, 1.42 FX multiplier, 25x earnings multiple after a control premium (for ~6-8 strong patent years remaining, >20% LTM earnings growth with visibility into continued strong double-digit expansion, plus some late and mid stage pipeline products - pushing closer to 30x if these, or the platform, could be developed further).
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-289
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.8¢ |
Change
0.013(3.97%) |
Mkt cap ! $637.2M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.5¢ | 32.0¢ | $1.069M | 3.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 263631 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 433233 | 17 |
View Market Depth
| Last trade - 13.03pm 30/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |